Part Two of a Two-Part Series
By Ramsey Baghdadi
Knocked Down But Not Out: Recovering From a Refuse to File
A "refusal-to-file" letter typically signals the end of a product's chances of ever getting approved in the US. Some companies, though, have returned from regulatory purgatory to get a review--and even approvals--after meeting FDA's demands.
More from Archive
More from Pink Sheet
• By
After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.
• By
Generic drug industry representatives applauded the FDA decision to bring back key staff in the Office of Generic Drugs that were laid off earlier this year.
• By
The White House is directing the Health and Human Services Department to replenish stockpiles of active pharmaceutical ingredients for “especially critical” medicines.